GlassScriptPhysician profile
Thomas A Goodman
NPI 1194702555
$211,269.00
in general payments reported to CMS, 2019-2025
55 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $40K · 2021: $33K · 2022: $19K · 2023: $22K · 2024: $25K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $12K · Travel and Lodging: $3,156 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,794.00 |
| Food and Beverage | $11,885.15 |
| Travel and Lodging | $3,155.88 |
| Education | $271.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $95,531.82 | 2019-2023 | Simponi Aria, Stelara, Tremfya |
| Janssen Biotech, INC. | $56,765.93 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Lilly USA, LLC | $23,523.83 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Regeneron Healthcare Solutions, INC. | $8,602.21 | 2019-2020 | |
| Horizon Therapeutics Plc | $7,467.07 | 2019-2023 | Krystexxa |
| Ucb, INC. | $2,481.09 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $2,469.08 | 2019-2025 | |
| Pfizer INC. | $2,221.11 | 2019-2025 | |
| Amgen INC. | $2,028.21 | 2019-2025 | Enbrel, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,929.93 | 2019-2025 | Benlysta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,709.38 | 2019-2025 | Farxiga, Breztri, Saphnelo |
| Novo Nordisk INC | $1,041.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Genzyme Corporation | $749.15 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.26 | 2019-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $510.53 | 2019-2025 | Orencia |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.